Focus anche sul trattamento innovativo e riabilitativo
Risultati per: Identificata la causa della progressione dell’Alzheimer nel cervello
Questo è quello che abbiamo trovato per te
Oms, incidenti stradali principale causa morte tra i 5-29 anni
Rapporto, 1,35 mln di morti ogni anno.
Gli indicatori di un cervello che invecchia
Ok Ue a farmaco anti-Alzheimer, il primo a rallentare malattia
Neurologi: ‘si apre una nuova storia per i pazienti’
Tumori al cervello, 9 bambini stanno meglio con le Car-T, per uno scomparsa la massa
In California una sperimentazione clinica contro una forma considerata letale. Per uno scomparsa la massa
Abstract 4147625: Cardiometabolic Syndrome and Incident Alzheimer’s Disease: The Predicative Value of Age and CMS Using Cox and Machine Learning Models
Circulation, Volume 150, Issue Suppl_1, Page A4147625-A4147625, November 12, 2024. Background:Cardiometabolic syndrome (CMS) poses a significant public health concern. The study aimed to investigate the predictive value of age and CMS for incident Alzheimer’s disease (AD) in women aged≥50.Methods:A cohort of women aged 50-79 (n= 63,117) who participated in the Women’s Health Initiative Observational Study (WHIOS) in 1993-1998, without baseline AD and followed through to March 1, 2019, were analyzed. CMS was defined as having ≥3 of five CMS components: large waist circumference, HBP, elevated triglycerides, elevated glucose, and low HDL-cholesterol. AD was classified by physician-diagnoses of incident AD. Hazards ratios (HR) of AD risk associated with CMS by age were analyzed using Cox’s proportional hazards regression analysis. Machine learning (ML)-XGBoost and Lasso Cox models clustered individuals with low, mild, moderate, and severe risk of incident AD.Results:During a median follow-up of 20 years (range: 3.36 to 23.36 years), 8340 developed incident AD. The incident rate (95%CI) of AD was 8.6 (8.1-9.1) per 1000 person-years (PY) in women with CMS, and 7.0 (6.9-7.2) per 1000 PY in those without CMS (p
Abstract 4136600: Hypertensive disorders of pregnancy and the risk of Dementia, Alzheimer’s disease, and Vascular Dementia. A Systematic review and Meta-analysis of 25,03,538 women participants.
Circulation, Volume 150, Issue Suppl_1, Page A4136600-A4136600, November 12, 2024. Background:Hypertensive disorders of pregnancy (HDP) are associated with maternal adverse cardiovascular outcomes. However, their association with maternal Dementia and Alzheimer’s disease is not well established with limited and conflicting results to date.Objective:We sought to evaluate the association between HDP and risk of incidence of Dementia, and Alzheimer’s disease.Methods:We performed a systematic review and meta-analysis of available literature that enrolled women with HDP and women without HDP groups. PubMed, Embase and ClinicalTrials.gov were systematically searched from inspection till May 2024 without any language restrictions. Adjusted hazard ratios (aHR) and 95% confidence intervals (CI) were pooled using a random-effect model.Results:A total of 8 studies with 2503538 patients (1,51,905 in women with HDP and 23,51,633 in the women without HDP group) were included. Pooled analysis shows that HDP women were having 37% higher risk of dementia (aHR, 1.37(95%CI: 1.27-1.46), P
Riviste le linee guida diagnostiche per l’Alzheimer
Alzheimer, vari tipi di vaccini abbassano i rischi anche del 30-40%
Aiutano a ‘ripulire’ accumuli tossici nel cervello
Alzheimer, una pdl per riconoscere e tutelare i caregiver
Lions italiani hanno contribuito a proposta con gruppo di lavoro
APOE3 Christchurch Heterozygosity and Autosomal Dominant Alzheimer’s Disease
New England Journal of Medicine, Volume 391, Issue 17, Page 1660-1661, October 31, 2024.
Una neuroscienziata fa 75 risonanze, così il cervello cambia con la pillola
La corteccia si riduce dell’1%, ma succede anche in pubertà e gravidanza
Pazienti a Meloni, l'Alzheimer sia una priorità per la politica
Affette 1,5 milioni di persone e numero è destinato ad aumentare
Convegno su salute del cervello, 'demenza sfida globale'
In fondazione Prada la seconda giornata di incontri
Blood Biomarkers to Detect Alzheimer Disease in Primary and Secondary Care
This prospective study evaluates a clinically available Alzheimer disease blood test in primary and secondary care using predefined biomarker cutoff values.
Blood Tests for Alzheimer Disease
This is a transformative time for patients with Alzheimer disease. Alzheimer disease is increasingly viewed as a treatable condition and managed like other major chronic diseases, such as heart disease and cancer. Management of Alzheimer disease includes early diagnosis with molecular confirmation, disease-modifying treatments that are initiated early in the disease course, better risk reduction and prevention strategies, and improved coordination of care.